Clinical trial
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
NCT01862640
Study timeline
Study start (actual)2013-07-11Date precision: day
Registry last updated2020-12-31
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Agitation Associated Withunresolved
Alzheimer's Diseaseunresolved
Alzheimer's Typeunresolved
Mental Disorderunresolved
Nervous System Diseasesunresolved
Interventions
Sponsors & collaborators
H. Lundbeck A/Scollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01862640 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.